Drug Shows Positive Response In Myeloma Patients in Australia
Immune System Therapeutics Limited, an Australian bio-therapeutic company, is recruiting patients for the second stage of a Phase II trial for a breakthrough antibody treatment for multiple myeloma.
The new experimental drug is called MDX-1097 and is an antibody that binds to the surface of myeloma cells, triggering the immune system to kill the cancer cells.
A review of safety and efficacy data by an independent Data Monitoring Committee (DMC) of data from the first six patients treated with the new monoclonal antibody therapy was positive. The trial is being conducted under the supervision of principal investigator and head of Malignant Haematology and Stem Cell Transplantation, Professor Andrew Spencer.